Kinahan J J, Otten M, Grindey G B
Cancer Res. 1979 Sep;39(9):3531-9.
Continuous exposure to inhibitory concentrations of methotrexate produces distinct rates of steady-state growth of murine leukemia L1210 and human leukemia CCRF-CEM cells in culture. Addition of thymidine to the medium produces reversal (6 to 40%) of this steady-state growth rate inhibition. This study utilized combinations of methotrexate and thymidine for an evaluation of the accompanying relationship between steady-state growth rate and changes in the ribo- and deoxyribonucleoside triphosphate pools. In L1210 cells exposed to methotrexate alone, the deoxythymidine 5'-phosphate (dTTP) pools decreased, whereas deoxyadenosine 5'-triphosphate, deoxyguanosine 5'-triphosphate, and deoxycytidine 5'-triphosphate (dCTP) remained relatively constant up to 70% inhibition of growth rate, with dCTP at a constant 112% of controls. The corresponding ribonucleoside triphosphates decreased only slightly. With the combination of methotrexate and thymidine resulting in up to 40% inhibition of growth rate, there was also a decrease in the dTTP pool while the other deoxyribonucleoside triphosphates remained relatively constant, and the corresponding ribonucleoside triphosphates again decreased only slightly. The dCTP pool was reduced to a constant 42% of control comparable to that produced by thymidine alone. With greater than 40% (with thymidine) or 70% (without thymidine) inhibition of growth rate, all pools decreased, but only dTTP was substantially reduced in proportion to the growth rate inhibition caused by methotrexate. The dTTP pool became depleted in spite of the presence of exogenous thymidine. Evaluation of CCRF-CEM cells indicated that inhibition of growth rate and nucleotide pool perturbations by methotrexate were similar to those observed in L1210 cells. However, in the presence of thymidine, inhibition of growth rate appeared related to decreased pools of dCTP, deoxyadenosine 5'-triphosphate, and deoxyguanosine 5'-triphosphate, rather than dTTP as was observed for L1210 cells. Hence, mammalian cells were capable of responding in a differential fashion to pharmacological perturbations, and this capacity may play a role in determining therapeutic selectivity. Since the ribonucleoside triphosphate decreases were slight and relatively uniform during methotrexate-induced perturbations, the deoxyribonucleoside triphosphate pools appear to be more directly related to inhibition of growth rate. The results are consistent with the concept that slight imbalances in the deoxyribonucleoside triphosphate pools dramatically inhibit DNA synthesis, as mediated through their interaction with DNA polymerase.
持续暴露于抑制浓度的甲氨蝶呤会使培养中的小鼠白血病L1210细胞和人白血病CCRF - CEM细胞产生不同的稳态生长速率。向培养基中添加胸苷可使这种稳态生长速率抑制发生逆转(6%至40%)。本研究利用甲氨蝶呤和胸苷的组合来评估稳态生长速率与核糖核苷三磷酸和脱氧核糖核苷三磷酸池变化之间的伴随关系。在仅暴露于甲氨蝶呤的L1210细胞中,脱氧胸苷5'-磷酸(dTTP)池减少,而脱氧腺苷5'-三磷酸、脱氧鸟苷5'-三磷酸和脱氧胞苷5'-三磷酸(dCTP)在生长速率抑制高达70%之前保持相对恒定,dCTP为对照的112%且恒定不变。相应的核糖核苷三磷酸仅略有下降。当甲氨蝶呤和胸苷联合使用导致生长速率抑制高达40%时,dTTP池也减少,而其他脱氧核糖核苷三磷酸保持相对恒定,相应的核糖核苷三磷酸再次仅略有下降。dCTP池降至对照的恒定42%,与单独使用胸苷时产生的情况相当。当生长速率抑制超过40%(使用胸苷时)或70%(不使用胸苷时),所有池均减少,但只有dTTP与甲氨蝶呤引起的生长速率抑制成比例地大幅减少。尽管存在外源性胸苷,dTTP池仍会耗尽。对CCRF - CEM细胞的评估表明,甲氨蝶呤对生长速率的抑制和核苷酸池的扰动与在L1210细胞中观察到的情况相似。然而,在胸苷存在的情况下,生长速率的抑制似乎与dCTP、脱氧腺苷5'-三磷酸和脱氧鸟苷5'-三磷酸池的减少有关,而不是像在L1210细胞中观察到的与dTTP有关。因此,哺乳动物细胞能够以不同的方式对药物扰动做出反应,这种能力可能在决定治疗选择性方面发挥作用。由于在甲氨蝶呤诱导的扰动过程中核糖核苷三磷酸的减少轻微且相对均匀,脱氧核糖核苷三磷酸池似乎与生长速率的抑制更直接相关。这些结果与脱氧核糖核苷三磷酸池的轻微失衡通过与DNA聚合酶的相互作用显著抑制DNA合成这一概念一致。